Arbutus Biopharma Corporation (NASDAQ:ABUS) currently has a daily average trading volume of 884.64K but it saw 1010411 shares traded on Thursday. With a market cap of 404.00M USD, stock’s current market price of $2.50 came falling about -2.34 while comparing to the previous closing price of $2.56. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.14 and as low as $1.85. In the recent trading on the day, stock has struck highest price mark of $2.54 while lowest mark touched by it was $2.41.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Taking a look at 20-day trading activity of Arbutus Biopharma Corporation (ABUS) gives us an average price of $2.56, while its current price level is -20.51% below from 52-week high level whereas it is 35.14% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.78 while that of 200 days or SMA-200 reads an average of $2.55. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.28% during that period while stretching the period over a month that decreases to 3.85%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.57 which implies that the stock is in neutral territory.
Arbutus Biopharma Corporation (ABUS)’s stock is currently under the radar of 5 analysts who are in consensus at a 12-month price target range of between $4.00 and $6.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $4.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $6.00. Average price target assigned by them is $5.40 which highlights an upside potential of 53.7% for the stock over that period. And to attain the median price target of $6.00 assigned by those analysts, stock has to add about 58.33% of value to its current levels.
Data by FactSet Research shows that 5 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 4 analysts suggested the investors to Buy the stock while 1 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.
Year-to-date it is 7.30% up and over the past year, the stock is showing an upside performance of 14.16%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of -$0.1 beat the consensus estimate of -$0.14 for the same. The company is expected to be releasing its next quarterly report in 08/03/2023, for which analysts forecasted an EPS of -$0.11 while estimate for next year EPS is -$0.45. For ABUS, analysts are forecasting an EPS-growth rate of 2.20% for current year and estimate for EPS growth in next year is -20.00%. In next quarter, company is expected to be making quarterly sales of $6.16 million as analysts are expecting the sales for current fiscal year at $25.07 million and seeing the company making $18.3 million in sales next year. Moreover, analysts are in estimates of $6.19 million for current-quarter revenue.
Currently, Arbutus Biopharma Corporation’s total number of outstanding shares is 161.64M with 25.22% of that held by the insiders while 32.79% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -51.10% and return on equity (ROE) at -48.30%. Stock’s beta reads 2.25. Stock has a price to book (P/B) ratio of 2.81 while price to sale or P/S ratio amounts to 12.21. Its return on asset (ROA) is -34.70% on average.
As per SEC documents, Vanguard Total Stock Market ETF shunned 3,300,543 of company’s common stock of worth $8.28 million as per recent closing price of the stock. Vanguard Total Stock Market ETF is not the only institutional holder which restructured its stake in Arbutus Biopharma Corporation, as iShares Russell 2000 ETF dumped 2,361,804 shares of worth $5.93 million to bring its holdings to a total of 34560.0 shares. In the most recent quarter, Vanguard Extended Market Index Fu came rising its stake by 0.14% in the company and now holds 1.56 million or 0.96% of the company’s stake having worth of about 3.92 million.
Leave a Reply